Clinical outcomes for patients with malignancies have improved in the past decade, in part due to the emergence of VEGF inhibitors, which are anticancer drugs that are commonly used to treat patients diagnosed with metastatic malignancies who have limited treatment options. However, clinicians must be aware that these agents present risk for cardiotoxicities.
The efficacy of these agents is due to their ability to suppress tumor growth by inhibiting VEGF, a proangiogenic growth factor that is overexpressed in a wide range of solid tumors. Given that angiogenesis is essential for (Read more...)
Uncategorized